Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Nov 23, 2016 11:30:25 GMT -5
Most diabetics are not aware of Afrezza but Wall Street and big pharma obviously are. I don't take your comments as insult, but as fear of future market share losses Afrezza will inflict.
Happy Thanksgiving!
|
|
|
|
Post by babaoriley on Nov 23, 2016 11:36:43 GMT -5
I understand where you're coming from Dicta, just wondering if your activities here are meant as therapy to address your anger with MNKD, and, if so, how's that working for you?
|
|
|
|
Post by dictatorsaurus on Nov 23, 2016 11:43:22 GMT -5
I understand where you're coming from Dicta, just wondering if your activities here are meant as therapy to address your anger with MNKD, and, if so, how's that working for you? Not working out too good since obviously I'm still blabbering away. I will say one thing though. I'm working behind the scenes trying to get a few things lined up for Mannkind. Whether or not any of it will see the light of day no one knows. |
|
|
|
Post by silentknight on Nov 23, 2016 12:43:43 GMT -5
When examining the current state of affairs, I think there positive developments that can be viewed favorably with MNKD 2.0, but in the totality of the circumstances, my assessment of the initiative would be that of disappointment. Mike and his team have done an incredible job of offering patient assistance with MNKD Cares and their willingness to reach out to physicians on behalf of patients is commendable. I also think they've done more outreach through various diabetic events and shows than SNY did, which is also appreciated.
Starting an operation like MNKD was forced to do, in very short order mind you, is nothing less than a miracle. However, I think it's pretty hard to argue with the fact that we've yet to see any meaningful results from said efforts. Scripts are hovering around (or below 300) which is minuscule in the grand scheme of things in terms of profitability. Doctors obviously are unwilling to prescribe Afrezza in any significant way and people are still encountering insurance issues, not to the same extent as before granted, but they still exist. A product of any sort will not sell if there is no demand.
Long story short, their strategy is not working. Afrezza is an incredible drug, but MNKD doesn't know how to, or can't, sell it. I remain invested but it's more for Epi and RLS potential than anything else. I've written off Afrezza entirely since after two years, and two different companies, we are no closer to market acceptance today than when we started. I am now where I was 3 or 4 years ago with my holdings in MNKD; i.e. awaiting FDA approval for pipeline candidates in the hopes that it goes somewhere. I thought Afrezza might. Sadly, it hasn't.
That being said, a .55 cent stock with a decent pipeline is worth the buy. If MNKD freed itself of Afrezza, you'd see the share price skyrocket...
|
|
|
|
Post by sophie on Nov 23, 2016 13:06:50 GMT -5
That being said, a .55 cent stock with a decent pipeline is worth the buy. If MNKD freed itself of Afrezza, you'd see the share price skyrocket... Agreed with some points in your post, but how do you think the last sentence makes sense in light of a diabetes market that is multiples larger than anaphylactic market as well as a product that just got voted to stay illegal? I think this company is a buy if they can start selling off deals for real money and/or they prove market viability. We're supposedly making headway in the former but none in the latter. In reality, MNKD has yet to show either to be the case. This is still a speculative stock. Personally, I'm glad that the share price is where it is. I think it's priced correctly because if it were higher, it'd just get knocked back down to this level. It's solely potential at this point. With over a decade of existence, potential hasn't amounted to much. Willing to give Matt a chance to change that... |
|
|
|
Post by babaoriley on Nov 23, 2016 13:07:57 GMT -5
"A product of any sort will not sell if there is no demand."
The demand is not there because such a small percentage of the diabetic public know about it, and many that do, don't have the whole picture. Demand has to be created by mass, effective advertising. SNY could have done this, and may have done it but for the most unfortunate change in CEO. Don't think we have anywhere near the money to do it, and persuade people that they do NEED Afrezza. That's what clever ads do, right?
Getting to the endos is fine, too, but I've look at the pressure that MNKD could generate by having a million or so diabetics say, "we want to try this stuff!" I can't imagine that in that case, you wouldn't get 20,000 new Rx over six months. Disclaimer: I haven't been able to imagine a whole lot lately that has come to pass.
|
|
|
|
Post by mockingjay on Nov 23, 2016 13:19:26 GMT -5
it doesn't matter if SNY did a good job or not, my main question so far is : why are the refills so low ? is always around 130 scripts weekly . What are the reasons ? why the afrezza users didn't wan to refill ?
|
|
|
|
Post by sophie on Nov 23, 2016 13:23:43 GMT -5
I agree with you. I'm just saying that it's illogical to assume we'll have greater success selling our other drugs in markets with much lower demand when we can't sell our best drug to the biggest market. It's why I'm glad the share price is where it is. If I'm already invested at this level, there's not much left to lose but a lot to gain. "The pop" is the only thing that's keeping me in MNKD. I don't want to miss out on a 100% increase day with the small chance that RLS keeps the lights on or advertising actually dramatically increases script counts.
|
|
|
|
Post by slugworth008 on Nov 23, 2016 13:27:16 GMT -5
"A product of any sort will not sell if there is no demand." The demand is not there because such a small percentage of the diabetic public know about it, and many that do, don't have the whole picture. Demand has to be created by mass, effective advertising. SNY could have done this, and may have done it but for the most unfortunate change in CEO. Don't think we have anywhere near the money to do it, and persuade people that they do NEED Afrezza. That's what clever ads do, right? Getting to the endos is fine, too, but I've look at the pressure that MNKD could generate by having a million or so diabetics say, "we want to try this stuff!" I can't imagine that in that case, you wouldn't get 20,000 new Rx over six months. Disclaimer: I haven't been able to imagine a whole lot lately that has come to pass. You nailed it Baba - Awareness is NOWHERE where it needs to be. And that IS fact not my opinion. The hardest part of any launch is to escape earth's gravity then it's smooth sailing at warp speeds. We're just blasting off with MNKD 2.0 |
|
|
|
Post by sportsrancho on Nov 23, 2016 13:30:29 GMT -5
"A product of any sort will not sell if there is no demand." The demand is not there because such a small percentage of the diabetic public know about it, and many that do, don't have the whole picture. Demand has to be created by mass, effective advertising. SNY could have done this, and may have done it but for the most unfortunate change in CEO. Don't think we have anywhere near the money to do it, and persuade people that they do NEED Afrezza. That's what clever ads do, right? Getting to the endos is fine, too, but I've look at the pressure that MNKD could generate by having a million or so diabetics say, "we want to try this stuff!" I can't imagine that in that case, you wouldn't get 20,000 new Rx over six months. Disclaimer: I haven't been able to imagine a whole lot lately that has come to pass. Ten thumbs up! Also not sure if more reps are going to do the trick. We need a team of people that will go out and give presentations to the head Endo's. Then get them set up with local reps. ( As done at Rancho Medical ) But agree most of the resources need to go to mass marketing creating patient demand!! |
|
|
|
Post by babaoriley on Nov 23, 2016 13:40:25 GMT -5
"We need a team of people that will go out and give presentations to the head Endo's."
Sports, do you think MNKD has anyone inhouse or otherwise that is capable of setting up such things with influential endos? I doubt it, if they did, they would be using that person extensively!
|
|
|
|
Post by mockingjay on Nov 23, 2016 13:44:21 GMT -5
"We need a team of people that will go out and give presentations to the head Endo's." Sports, do you think MNKD has anyone inhouse or otherwise that is capable of setting up such things with influential endos? I doubt it, if they did, they would be using that person extensively! you guys are funny, it's not difficult to get people to do the presentations, they are the professionals, they can do the jobs . The main problem is how to convince the endos to sit 1 hour for their presentation . It's not easy these days if you are a no name company (it's must easier if your company name is Sanofi, Novo etc ... because they have plenty of gifts for these endos) . |
|
|
|
Post by silentknight on Nov 23, 2016 14:33:58 GMT -5
"A product of any sort will not sell if there is no demand." The demand is not there because such a small percentage of the diabetic public know about it, and many that do, don't have the whole picture. Demand has to be created by mass, effective advertising. SNY could have done this, and may have done it but for the most unfortunate change in CEO. Don't think we have anywhere near the money to do it, and persuade people that they do NEED Afrezza. That's what clever ads do, right? Getting to the endos is fine, too, but I've look at the pressure that MNKD could generate by having a million or so diabetics say, "we want to try this stuff!" I can't imagine that in that case, you wouldn't get 20,000 new Rx over six months. Disclaimer: I haven't been able to imagine a whole lot lately that has come to pass. You're 100% correct, assuming you could get that many patients to say it. My point is that MNKD can't. It's not a knock on the company or it's management. I simply think MNKD is in over it's head in the marketing aspects. A for effort but they can't sell the drug at least not from what we've seen so far. We've now had two companies with different strategies have little to no success in marketing the drug. The cleaned up balance sheet is nice, and I'm very happy about that, but as we've seen, the market doesn't really care. It wants sales. Period. Perhaps EPI would end up the same way, but I want to believe that MNKD now knows that it needs to partner or Epihale or whatever it will be called will end up in the same situation as Afrezza is: a relatively unknown alternative to a major health issue that if utilized, would be better than all existing alternatives, but commercially has turned out to be a major bust. |
|
|
|
Post by sportsrancho on Nov 23, 2016 14:36:03 GMT -5
"We need a team of people that will go out and give presentations to the head Endo's." Sports, do you think MNKD has anyone inhouse or otherwise that is capable of setting up such things with influential endos? I doubt it, if they did, they would be using that person extensively! you guys are funny, it's not difficult to get people to do the presentations, they are the professionals, they can do the jobs . The main problem is how to convince the endos to sit 1 hour for their presentation . It's not easy these days if you are a no name company (it's must easier if your company name is Sanofi, Novo etc ... because they have plenty of gifts for these endos) . I'm talking about people that already have the connections. ( Not reps with gifts ) IMO we need a different way of marketing Afrezza and MNKD should take advantage of these connections on a continuing basis. |
|
|
|
Post by mockingjay on Nov 23, 2016 14:57:35 GMT -5
you guys are funny, it's not difficult to get people to do the presentations, they are the professionals, they can do the jobs . The main problem is how to convince the endos to sit 1 hour for their presentation . It's not easy these days if you are a no name company (it's must easier if your company name is Sanofi, Novo etc ... because they have plenty of gifts for these endos) . I'm talking about people that already have the connections. ( Not reps with gifts ) IMO we need a different way of marketing Afrezza and MNKD should take advantage of these connections on a continuing basis. more than 50% of primary care physician doesn't want to see a pharma rep , and the rest 50% have a really good relation with a big pharma company (with plenty of gifts per year) .. how can a new rep of a new company have a good connections with an endo ?, you tell me .. (all the top reps are still with the big pharma, you can not get these reps easily, even if you can get them, you need to spend money crazily to get access to these endos , and Mannkind is just a very small pharma company and doesn't have enough money to give gifts to these endos . (I saw many doctors have gifts : tickets to sport events, restaurant Christmas gifts, wine bottle gifts, free flight tickets to conferences etc .. ) and they (the endos) have relations with these big pharmas for many years already . An individual pharma rep doesn't have this kind of power . |
|
